Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Biotechnology Value Fund LP and Oncomed Pharmaceuticals Inc (OMED)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Fund 0 1,372,923 1,372,923 3.6%
Biotechnology Value Fund II 0 899,819 899,819 2.4%
Biotechnology Value Trading Fund OS 0 249,098 249,098 Less than 1%
BVF Partners OS Ltd 0 249,098 249,098 Less than 1%
BVF Partners 0 2,985,489 2,985,489 7.9%
BVF Inc 0 2,985,489 2,985,489 7.9%
Mark N. Lampert 0 2,985,489 2,985,489 7.9%

Page 1 of 13 – SEC Filing

 UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c),
AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No.
)1

OncoMed Pharmaceuticals, Inc.

 (Name of Issuer)

Common Stock, $0.001 par value

 (Title of Class of Securities)

68234X102

 (CUSIP Number)

April 17, 2017

 (Date of Event Which Requires Filing of this
Statement)

Check the appropriate box
to designate the rule pursuant to which this Schedule is filed:

   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)

1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 2 of 13 – SEC Filing

1 NAME OF REPORTING PERSON
Biotechnology Value Fund, L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 1,372,923
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
1,372,923
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,372,923
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.6%
12 TYPE OF REPORTING PERSON
PN
2

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 3 of 13 – SEC Filing

1 NAME OF REPORTING PERSON
Biotechnology Value Fund II, L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 899,819
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
899,819
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
899,819
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.4%
12 TYPE OF REPORTING PERSON
PN
3

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 4 of 13 – SEC Filing

1 NAME OF REPORTING PERSON
Biotechnology Value Trading Fund OS LP
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 249,098
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
249,098
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
249,098
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
Less than 1%
12 TYPE OF REPORTING PERSON
PN
4

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 5 of 13 – SEC Filing

1 NAME OF REPORTING PERSON
BVF Partners OS Ltd.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 249,098
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
249,098
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
249,098
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
Less than 1%
12 TYPE OF REPORTING PERSON
CO
5

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 6 of 13 – SEC Filing

1 NAME OF REPORTING PERSON
BVF Partners L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 2,985,489
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
2,985,489
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,985,489
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.9%
12 TYPE OF REPORTING PERSON
PN, IA
6

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 7 of 13 – SEC Filing

1 NAME OF REPORTING PERSON
BVF Inc.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 2,985,489
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
2,985,489
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,985,489
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.9%
12 TYPE OF REPORTING PERSON
CO
7

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 8 of 13 – SEC Filing

1 NAME OF REPORTING PERSON
Mark N. Lampert
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 2,985,489
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
2,985,489
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,985,489
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.9%
12 TYPE OF REPORTING PERSON
IN
8

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 9 of 13 – SEC Filing

Item 1(a). Name of Issuer:

OncoMed Pharmaceuticals, Inc., a Delaware corporation (the
“Issuer”).

Item 1(b). Address of Issuer’s Principal Executive Offices:

800 Chesapeake Drive

Redwood City, California 94063

Item 2(a). Name of Person Filing
Item 2(b). Address of Principal Business Office or, if None, Residence
Item 2(c). Citizenship

Biotechnology Value Fund, L.P. (“BVF”)

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. (“BVF2”)

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS
LP (“Trading Fund OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. (“Partners
OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners L.P. (“Partners”)

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF Inc.

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert (“Mr. Lampert”)

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: United States

Each of the foregoing is referred to
as a “Reporting Person” and collectively as the “Reporting Persons.”

Item 2(d). Title of Class of Securities:

Common Stock, par value $0.001 per share (the “Common
Stock”)

9

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 10 of 13 – SEC Filing

Item 2(e). CUSIP Number:

68234X102

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person
Filing is a:
/x/ Not applicable.
(a) / / Broker or dealer registered under Section 15 of the Exchange Act.
(b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
(c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d) / / Investment company registered under Section 8 of the Investment Company Act.
(e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
(j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____
Item 4. Ownership
(a) Amount beneficially owned:

As of the close of business on April
27, 2017 (i) BVF beneficially owned 1,372,923 shares of Common Stock, (ii) BVF2 beneficially owned 899,819 shares of Common Stock,
and (iii) Trading Fund OS beneficially owned 249,098 shares of Common Stock.

Partners OS as the general partner
of Trading Fund OS may be deemed to beneficially own the 249,098 shares of Common Stock beneficially owned by Trading Fund OS.

Partners, as the general partner of
BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the
2,985,489 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and certain Partners managed
accounts (the “Partners Managed Accounts”), including 463,649 shares of Common Stock held in the Partners Managed Accounts.

10

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 11 of 13 – SEC Filing

BVF Inc., as the general partner of
Partners, may be deemed to beneficially own the 2,985,489 Common Stock beneficially owned by Partners.

Mr. Lampert, as a director and officer
of BVF Inc., may be deemed to beneficially own the 2,985,489 Common Stock beneficially owned by BVF Inc.

The foregoing should not be construed
in and of itself as an admission by any Reporting Person as to beneficial ownership of any Common Stock owned by another Reporting
Person. Partners OS disclaims beneficial ownership of the Common Stock beneficially owned by Trading Fund OS. Each of Partners,
BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and
the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or
entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based
on 37,623,443 Common Stock outstanding as disclosed in the Issuer’s Definitive Proxy Statement on Form DEF 14A filed with
the Securities and Exchange Commission on April 13, 2017.

As of the close of business on April
27, 2017 (i) BVF beneficially owned approximately 3.6% of the outstanding Common Stock, (ii) BVF2 beneficially owned approximately
2.4% of the outstanding Common Stock, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Common Stock (iv)
Partners OS may be deemed to beneficially own less than 1% of the outstanding Common Stock, and (v) each of Partners, BVF Inc.
and Mr. Lampert may be deemed to beneficially own approximately 7.9% of the outstanding Common Stock (approximately 1.2% of which
is held in the Partners Managed Accounts).

(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

11

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 12 of 13 – SEC Filing

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Partners, BVF Inc. and Mr. Lampert
share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners
Managed Accounts.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on
by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of
the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

12

Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!

Page 13 of 13 – SEC Filing

SIGNATURE

After reasonable inquiry
and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement
is true, complete and correct.

Dated: April 27, 2017

BIOTECHNOLOGY VALUE FUND, L.P. BVF INC.
By: BVF Partners L.P., its general partner By: /s/ Mark N. Lampert
By: BVF Inc., its general partner Mark N. Lampert
  President
By:

/s/ Mark N. Lampert

Mark N. Lampert  
President /s/ Mark N. Lampert
  MARK N. LAMPERT
BIOTECHNOLOGY VALUE FUND II, L.P.
 
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
 
By:

/s/ Mark N. Lampert

Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
 
By:

/s/ Mark N. Lampert

Mark N. Lampert
President
BVF PARTNERS OS LTD.
By: BVF Partners L.P., its sole member
By: BVF Inc., its general partner
 
By:

/s/ Mark N. Lampert

Mark N. Lampert
President
Biotechnology Value Trading Fund OS LP
By: BVF Partners L.P., its investment manager
By: BVF Inc., its general partner
 
By:

/s/ Mark N. Lampert

Mark N. Lampert
13
Follow Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
Trade (NASDAQ:OMED) Now!